• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[恶性血液系统疾病。诊断与治疗。一份清晰报告]

[Malignant hematologic diseases. Diagnosis and treatment. A clearing report].

作者信息

Birgens H, Christensen B E, Hansen N E, Jensen M K, Junker K, Jørgensen F S, Nielsen J L, Nissen N I

机构信息

Medicinsk haematologisk afdeling C, Københavns Amts Sygehus i Gentofte, Hellerup.

出版信息

Ugeskr Laeger. 1991 Jun 3;153(23):1638-47.

PMID:2058026
Abstract

The malignant haematological disorders comprise the main groups leukemia, malignant lymphoma and multiple myeloma and the potentially malignant disorders: myelodysplastic syndrome, polycythaemia vera, myelofibrosis and M-component of uncertain significance. The common feature of all these disorders is monoclonality, i.e. they originate from one single cell. Around 2,000 new cases are diagnosed per year in Denmark. Because of the relative small number of patients, complex diagnosis and treatment (especially the possibility of cure on intensive treatment) a high degree of centralization is warranted to secure an evenly distributed high level of patient care and research. The present rules for referral of patients are unsatisfactory. A new referral system is proposed based on a common set of rules, agreed upon by five haematological centers in Denmark and the surrounding region, comprising diagnostic procedures, treatment, research and development for all haematological patients in the area. Based on these common rules (functional centralization) it is decided whether the individual patient can be treated in the primary hospital or should be referred to a center (geographical centralization). Recommendations about diagnosis, treatment and referral are made in this report. Detailed suggestions are given for diseases which may be treated locally whereas no detailed regimens are given for diseases and disease stages which should be centralized. In the latter cases, the main emphasis is placed on a presentation of treatment results.

摘要

恶性血液系统疾病主要包括白血病、恶性淋巴瘤和多发性骨髓瘤等组群,以及潜在恶性疾病:骨髓增生异常综合征、真性红细胞增多症、骨髓纤维化和意义未明的M成分。所有这些疾病的共同特征是单克隆性,即它们都起源于单个细胞。丹麦每年约有2000例新病例被诊断出来。由于患者数量相对较少、诊断和治疗复杂(特别是强化治疗有可能治愈),因此有必要进行高度集中化,以确保患者护理和研究水平的均匀分布。目前的患者转诊规则并不令人满意。基于丹麦及其周边地区的五个血液学中心商定的一套共同规则,提出了一种新的转诊系统,该系统包括该地区所有血液学患者的诊断程序、治疗、研究和开发。根据这些共同规则(功能集中化),决定个体患者是可以在基层医院接受治疗还是应转诊至中心(地理集中化)。本报告提出了关于诊断、治疗和转诊的建议。对于可以在当地治疗的疾病给出了详细建议,而对于应集中治疗的疾病和疾病阶段则没有给出详细方案。在后一种情况下,主要重点是呈现治疗结果。

相似文献

1
[Malignant hematologic diseases. Diagnosis and treatment. A clearing report].[恶性血液系统疾病。诊断与治疗。一份清晰报告]
Ugeskr Laeger. 1991 Jun 3;153(23):1638-47.
2
[Interferon therapy in hematologic neoplasms].[血液肿瘤中的干扰素治疗]
Wien Klin Wochenschr. 1988 Aug 5;100(15):497-504.
3
The value of cell cultures for the diagnosis of mixed myelodysplastic/myeloproliferative disorders.细胞培养在混合性骨髓增生异常/骨髓增殖性疾病诊断中的价值。
Haematologica. 1998 Jan;83(1):3-7.
4
2nd International Congress on Leukemia, Lymphoma and Myeloma.第二届白血病、淋巴瘤和骨髓瘤国际大会。
Expert Rev Hematol. 2009 Oct;2(5):509-12. doi: 10.1586/ehm.09.50.
5
Lymphoproliferative and myeloproliferative disease in Tasmania.
Natl Cancer Inst Monogr. 1977 Dec;47:37-9.
6
[Leukemias and malignant lymphomas in children].[儿童白血病和恶性淋巴瘤]
Ugeskr Laeger. 1999 Apr 12;161(15):2191-5.
7
Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.组织病理学在急性髓系白血病、骨髓增生异常综合征及骨髓增生异常/骨髓增殖性疾病的诊断与分类中的应用
Pathobiology. 2007;74(2):97-114. doi: 10.1159/000101709.
8
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.甲磺酸伊马替尼治疗难治性或复发性急性髓系白血病、高危骨髓增生异常综合征和骨髓增殖性疾病患者的结果。
Cancer. 2003 Jun 1;97(11):2760-6. doi: 10.1002/cncr.11416.
9
[Optimising therapy in patients with haematological malignancies].[血液系统恶性肿瘤患者的治疗优化]
Bull Cancer. 2008 Oct;95(10):959-62. doi: 10.1684/bdc.2008.0718.
10
[10 years' experiences with flow cytometric immunological phenotyping in malignant hematologic diseases].[恶性血液病流式细胞免疫表型分析的10年经验]
Ugeskr Laeger. 1996 Oct 21;158(43):6098-102.